100000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
link:presentationLink
link:calculationLink
link:definitionLink
100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
link:presentationLink
link:calculationLink
link:definitionLink
100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)
link:presentationLink
link:calculationLink
link:definitionLink
100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
link:presentationLink
link:calculationLink
link:definitionLink
100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Basis of Presentation and New Accounting Standards
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Use of Estimates
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Liquidity and Going Concern
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Fair Value Measurements
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Term Loan Obligations
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Line of Credit Facility
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - Biocept Asset Acquisitions
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Loss per Share
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Grant Revenue
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - License Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Stockholders' Deficit
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Stock-based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - COVID-19 Pandemic and CARES Act
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Basis of Presentation and New Accounting Standards (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Fair Value Measurements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Loss per Share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Commitments and Contingencies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Stock-based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Basis of Presentation and New Accounting Standards - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Use of Estimates - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Liquidity and Going Concern - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Fair Value Measurements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Fair Value Measurements - Summary of Key Inputs Used in Valuation of Liability Classified Warrants (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Value of Warrant Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Term Loan Obligations - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Line of Credit Facility - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Loss per Share - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Loss per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share of Common Stock (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Biocept Asset Acquisitions - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Grant Revenue - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Commitments and Contingencies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - License Agreements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Stockholders' Deficit - Preferred Stock (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Stockholders' Deficit - Common stock (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Stockholders' Deficit - Warrants (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Stock-based Compensation - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Subsequent Events - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Statement [Line Items]
Statement [Line Items]
Period for regain compliance
Period For Regain Compliance
Period for regain compliance.
Weighted Average Remaining Contractual Life (years) [Roll Forward]
Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]
Debt Instrument
Debt Instrument [Axis]
May 2024 private placement.
May 2024 Private Placement [Member]
May 2024 Private Placement [Member]
Plan Name
Plan Name [Domain]
Purchase of treasury stock
Payments for Repurchase of Equity
Payments for Repurchase of Equity, Total
Entity Address, Postal Zip Code
Entity Address Postal Zip Code
Fair Value, Recurring and Nonrecurring [Table]
Entity Incorporation, State or Country Code
Entity Incorporation State Country Code
Business Combination, Acquisition Related Costs
Costs of acquisitions
Interest
Interest Paid Net
Number of Operating Segments
Number of operating segment
Exercisable at September 30, 2024 (in dollars per share)
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
Reverse stock split
Stockholders' Equity, Reverse Stock Split
Balance (in shares)
Balance (in shares)
Shares Outstanding
Fair Value Hierarchy and NAV [Axis]
Level 2 [Member]
Fair Value, Inputs, Level 2 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Closing bid price
Closing Bid Price
Closing bid price.
Long-Term Debt, Current Maturities, Total
Term loan obligation, current
Long Term Debt Current
Commitments and Contingencies
Commitments And Contingencies Disclosure [Text Block]
Schedule Of Stock By Class [Table]
Schedule Of Stock By Class [Table]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Schedule of Changes in Fair Value of Warrant Liabilities
Product and Service [Axis]
Debt principal repayment start date
Debt Principal Repayment Start Date
Debt principal repayment start date.
Depreciation, Depletion and Amortization, Total
Depreciation and amortization
Depreciation Depletion And Amortization
Lorem Vascular Pte Ltd [Member]
Lorem Vascular Pte Ltd [Member]
Lorem Vascular, Pte. Ltd.
Stock option vesting percentage
Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
Collaborative Arrangement and Arrangement Other than Collaborative
Arrangements And Nonarrangement Transactions [Member]
Number of stock repurchased
Stock Repurchased During Period, Shares
Payments to Acquire Productive Assets
Total cash payment
Total cash payment
Piramal Pharma Solutions, Inc. [Member]
Piramal Pharma Solutions Inc [Member]
Piramal pharma solutions inc.
Interest expense
Interest Expense, Nonoperating
Interest Expense, Nonoperating, Total
Stockholders Equity Note Disclosure [Text Block]
Stockholders' Deficit
Class of Warrant or Right
Class Of Warrant Or Right [Axis]
Grant Revenue
Revenue from Contract with Customer [Text Block]
Cash paid during period for:
Cash Paid During Period For [Abstract]
Cash paid during period for:
Congressionally Directed Medical Research Programs [Member]
Congressionally Directed Medical Research Programs [Member]
Congressionally directed medical research programs.
Sale of Stock
Sale Of Stock Name Of Transaction [Domain]
Cash and Cash Equivalents [Domain]
Change in fair value of warrants
Change In Fair Value Of Warrants
Change in fair value of warrants.
2018 Rights Offering [Member]
Two Thousand Eighteen Rights Offering [Member]
Two thousand eighteen rights offering.
2022 Purchase Agreement [Member]
Two Thousand and Twenty Two Purchase Agreement [Member]
Two thousand and twenty two purchase agreement.
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Entity Central Index Key
Entity Central Index Key
Outstanding Warrants [Member]
Warrant [Member]
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
Cancelled/expired (in shares)
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Increase Decrease In Operating Capital [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Initial Subscription.
Initial Subscription [Member]
Common stock, shares issued (in shares)
Common Stock Shares Issued
Rights related to distribution of assets.
Rights Related To Distribution Of Assets
Rights related to distribution of assets
Percentage of grant proceeds with interest not exceed annually
Percentage Of Grant Proceeds With Interest Not Exceed Annually
Percentage of grant proceeds with interest not exceed annually.
Reclass of warrants to equity
Stock Issued During Period, Value, Reclassification of warrants to equity
Stock issued during period, value, reclassification of warrants to equity.
Fair Value Measurement Inputs and Valuation Techniques [Table]
Short-Term Debt [Text Block]
Line of Credit Facility
Convertible Preferred Stock [Member]
Preferred Stock [Member]
Preferred Stock [Member]
Income Statement [Abstract]
Entity Address, State or Province
Entity Address State Or Province
Purchase of short-term investments
Payments to Acquire Short-Term Investments
Collateralized marketable securities
Marketable Securities
Marketable Securities, Total
Warrants Policy.
Warrants Policy [Policy Text Block]
Warrants
Exercisable at September 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Liability Class [Axis]
Exercise of pre-funded warrants (in Shares)
Exercise Of Pre-funded Warrants Shares
Exercise of pre-funded warrants shares.
Series F Preferred Stock [Member]
Series F Preferred Stock [Member]
Treasury stock, shares
Treasury Stock, Common, Shares
Cover [Abstract]
License Agreement [Abstract]
License agreement abstract.
Subsequent Event [Line Items]
Earnings Per Share, Basic, Total
Earnings Per Share Basic
Net loss per share of common stock - basic
Term Loan [Member]
Term Loan [Member]
Second amendment to the amended and restated loan and security agreement.
Lessee, operating lease, option to extend
Lessee Operating Lease Option To Extend
Equity Incentive Plans [Member]
Equity Incentive Plans [Member]
Equity incentive plans.
Operating expenses:
Operating Expenses [Abstract]
Reclassification to equity
Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification To Equity
Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, reclassification to equity.
Asset Acquisition [Axis]
Retained Earnings (Accumulated Deficit), Total
Accumulated deficit
Retained Earnings Accumulated Deficit
Accumulated deficit
Plan Name
Plan Name [Axis]
Balance as of September 30, 2024 (in shares)
Balance as of December 31, 2023 (in shares)
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
Current assets:
Assets Current [Abstract]
Common stock capital shares reserved for future issuance
Number of shares reserved for issuance and sale
Common Stock, Capital Shares Reserved for Future Issuance
Regain compliance expiry date.
Regain Compliance Expiry Date
Regain compliance expiry date
Accounting Standards Update and Change in Accounting Principle [Abstract]
Investment Type
Investment Type [Axis]
Net cash used in operating activities
Net cash used in operating activities
Net Cash Provided By Used In Operating Activities
Common stock issued in payment for in process research and development
Stock Issued
Product and Service [Domain]
Lessee, operating lease, term of contract
Lessee Operating Lease Term Of Contract
Maximum value of shares to be issued under agreement
Maximum Value of Shares to be Issued Under Agreement
Maximum value of shares to be issued under agreement.
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Recorded Unconditional Purchase Obligation by Category of Item Purchased
Recorded Unconditional Purchase Obligation By Category Of Item Purchased [Axis]
Property, Plant and Equipment, Net, Total
Property and equipment, net
Property Plant And Equipment Net
Cash flows used in operating activities:
Net Cash Provided By Used In Operating Activities [Abstract]
Services Agreement [Member]
Services Agreement [Member]
Services agreement.
Recurring Basis [Member]
Fair Value, Recurring [Member]
Other income (expense):
Other Income And Expenses [Abstract]
Common stock, par value
Common stock, par value (in dollars per share)
Common Stock Par Or Stated Value Per Share
Measurement Input Type [Domain]
Statement Of Cash Flows [Abstract]
2015 Plan [Member]
Stock Based Compensation2015 Equity Incentive Plan1 [Member]
Stock based compensation 2015 equity incentive plan 1 member.
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
Change in fair value of warrants
Number of securities called by warrant or right
Number of shares callable by warrants (in shares)
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
Entity
Entity [Domain]
Redemption of short-term investments
Redemption of Short-Term Investments
Redemption of Short-Term Investments
Pershing Credit Facility.
Pershing Credit Facility [Member]
Pershing Credit Facility [Member]
Equity Components [Axis]
Equity Components
Statement Equity Components [Axis]
Recorded Unconditional Purchase Obligation [Line Items]
Recorded Unconditional Purchase Obligation [Line Items]
Entity Address, Address Line One
Entity Address Address Line1
Charlottesville [Member]
Charlottesville [Member]
Charlottesville
Schedule of Computation of Basic and Diluted Net Loss Per Share of Common Stock
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Subsequent Event Type [Axis]
Nonoperating Income Expense
Total other income (expense)
Schedule of Antidilutive Securities Excluded from Diluted Loss per Share
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]
Unrealized gain on available-for-sale securities
Debt Securities, Available-for-Sale, Unrealized Gain
Recently Issued Accounting Pronouncements
New Accounting Pronouncements And Changes In Accounting Principles [Text Block]
License Agreements
License Agreement Disclosure [Text Block]
Disclosure of accounting policy for license agreement.
Amendment Flag
Amendment Flag
Increase (Decrease) in Operating Lease Liability
Change in operating lease liabilities
Noncurrent operating lease liability
Operating Lease Liability Noncurrent
Outstanding Stock Options [Member]
Options [Member]
Options.
Debt Instrument, Name
Debt Instrument Name [Domain]
Preferred Stock, Voting Rights
Preferred stock, voting rights
SOFR [Member]
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]
Net loss
Net loss
Exercisable at September 30, 2024 (in shares)
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
Variable Rate
Variable Rate [Domain]
Loss on disposal of property and equipment
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property
Loss on disposal of property and equipment
Equity Component [Domain]
Equity Component
Equity Component [Domain]
Statistical Measurement [Domain]
Statistical Measurement
Range [Member]
General and Administrative Expense, Total
General and administrative
General And Administrative Expense
Deferred Income, Noncurrent
Deferred grant liability
Financing expense.
Financing Expense
Financing expense
Financing expense
Stock option contractual term
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
Treasury Stock [Member]
Treasury Stock, Common [Member]
Disaggregation of Revenue [Table]
Research and development award period
Research and Development Award Period
Research and development award period.
Proceeds from Lines of Credit, Total
Proceeds from Lines of Credit
Proceeds from credit facility
Payment for tech transfer and validation fee
Payment For Tech Transfer And Validation Fee
Payment for tech transfer and validation fee.
Preferred stock, shares issued (in shares)
Preferred Stock Shares Issued
Lincoln Park Capital Fund, LLC [Member]
Lincoln Park Capital Fund L L C [Member]
Lincoln park capital fund, LLC.
Lessee, Operating Lease, Discount Rate
Operating lease discount rate
Consideration paid to preferred stock holders.
Consideration Paid To Preferred Stock Holders
Consideration paid to preferred stock holders
Use Of Estimates [Abstract]
Use of Estimates [Abstract]
Investments
Short-Term Investments
Short-Term Investments, Total
Rent expense
Operating Lease Expense
Vested and expected to vest at September 30, 2024 (in dollars per share)
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
Cancelled/expired (in dollars per share)
Loan and Security Agreement [Member]
Loan And Security Agreement [Member]
Loan and security agreement.
Increase decrease in grant receivable.
Increase Decrease In Grant Receivable
Grant receivable
Collaborative Arrangement and Arrangement Other than Collaborative
Type Of Arrangement [Axis]
Class of Stock
Class Of Stock [Domain]
Period exercisable from the date of issuance
Period Exercisable From The Date Of Issuance
Refers to the period exercisable from the date of issuance.
Common Stock, Shares, Outstanding, Ending Balance
Common Stock, Shares, Outstanding, Beginning Balance
Common stock, shares outstanding (in shares)
Common Stock Shares Outstanding
Options [Roll Forward]
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward
Consecutive business days
Consecutive Business Days
Consecutive business days.
Preferred stock, par value (in dollars per share)
Preferred Stock Par Or Stated Value Per Share
Contract effective date
Contract Effective Date
Contract effective date.
Proceeds from Issuance or Sale of Equity, Total
Proceeds from Issuance or Sale of Equity
Proceeds from sale of common stock, warrants and pre-funded warrants, net
UTHSCSA license agreement member.
U T H S C S A License Agreement [Member]
UTHSCSA License Agreement [Member]
Asset Acquisition [Abstract]
Entity Interactive Data Current
Entity Interactive Data Current
Operating leases, expiration date
Lease Expiration Date1
Warrant Liability [Member]
Warrant liability.
Warrant Liability [Member]
Accounting Standards Update [Domain]
Document Quarterly Report
Document Quarterly Report
Statistical Measurement [Axis]
Statistical Measurement
Range [Axis]
Grant amount awarded
Contract with Customer, Asset, before Allowance for Credit Loss
Fair Value
Assets, Fair Value Disclosure
Assets, Fair Value Disclosure, Total
Related Party
Related and Nonrelated Parties [Domain]
Summary of Future Minimum Annual Lease Payments under Operating Leases
Lessee Operating Lease Liability Maturity Table [Text Block]
Liquidity [Abstract]
Liquidity Abstract
Initial commitment shares
Initial Commitment Shares
Initial commitment shares.
Sale of the Japanese Subsidiary and Certain Assets [Member]
Sale Of Japanese Subsidiary And Certain Assets [Member]
Sale of the japanese subsidiary and certain assets.
Securities remaining and available for future issuances (in shares)
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
Basis of Presentation and New Accounting Standards
Basis Of Presentation And Significant Accounting Policies [Text Block]
Weighted average period for recognition of cost
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
Proceeds from Issuance of Private Placement
Proceeds from private placement
Aggregate upfront gross proceeds from private placement
Cash and Cash Equivalents [Axis]
Total assets
Assets
Debt Instrument [Table]
Debt Instrument [Table]
Offering cost
Offering costs.
Offering Costs
Offering expenses
Recorded Unconditional Purchase Obligation, Category [Domain]
Recently Issued Accounting Pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Entity Address, City or Town
Entity Address City Or Town
Contract termination date
Contract Termination Date
Contract termination date.
Interest Rate Floor [Member]
Interest Rate Floor [Member]
Original loan amount
Debt Instrument Face Amount
Closing price per share
Share Price
Offering price
Sale of Stock, Transaction Date
Sale closed date
Stock-based Compensation
Disclosure Of Compensation Related Costs Share Based Payments [Text Block]
Operating lease, weighted average discount rate
Operating Lease Weighted Average Discount Rate Percent
Grant [Member]
Grant [Member]
Fair Value Disclosures [Abstract]
Grant funding term
Grant Funding Term
Grant funding term.
Stockholders' equity requirement
Issue and sale of stock, net
Sale and issuance of common stock, net
Current liabilities:
Liabilities Current [Abstract]
Stock Redeemed or Called During Period, Shares
Redemption of Series F preferred stock (in shares)
Document Type
Document Type
Minimum liquidity covenant
Minimum Liquidity Covenant Amount
Minimum liquidity covenant amount.
Accounting Standards Update [Axis]
Title of 12(b) Security
Security12b Title
Cash and Cash Equivalents, at Carrying Value, Total
Cash and cash equivalents
Cash And Cash Equivalents At Carrying Value
Summary of Lease Costs
Lease Cost Table [Text Block]
Statement Of Stockholders Equity [Abstract]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Beginning balance
Ending Balance
Document Fiscal Period Focus
Document Fiscal Period Focus
Research and development expense
Research and Development Expense, Total
Research and development
Research And Development Expense
Granted (in shares)
Common stock shares to be issued (in shares)
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
Subsequent Event Type [Domain]
LIBOR [Member]
LIBOR [Member]
LIBOR.
Stock Option Activity
Schedule Of Share Based Compensation Activity Table [Text Block]
Measurement Input, Expected Term [Member]
Expected Term [Member]
Representative Warrants [Member]
Representative Series U Warrant [Member]
Representative Series U Warrant.
Initial commitment fee paid in cash
Initial Commitment Fee
Initial commitment fee.
Warrant exercise price (in dollars per share)
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
Financial Instruments
Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]
Series F Convertible Preferred Stock.
Series F Convertible Preferred Stock [Member]
Warrant expiration date
Class Of Warrant Or Right Expiration Date
The date that the warrant or right expires.
Sale of Stock
Subsidiary Sale Of Stock [Axis]
Cash flows used in investing activities:
Net Cash Provided By Used In Investing Activities [Abstract]
Investments
Investment Type Categorization [Member]
Date from which warrants are exercisable
Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
COVID-19 Pandemic and CARES Act
Unusual Or Infrequent Items Disclosure [Text Block]
Grant revenue
Grant revenue recognized
Revenue from Contract with Customer, Excluding Assessed Tax
Deferred grant liability
Deferred Income, Current
Compensatory damages and operational
Compensatory Damages And Operational
Compensatory damages and operational.
Line of Credit Facility [Line Items]
Credit Facility [Domain]
Aggregated Intrinsic Value [Roll Forward]
Share Based Compensation Arrangement by Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]
Share based compensation arrangement by share based payment award options aggregate intrinsic value.
Entity Address, Address Line Two
Entity Address Address Line2
Litigation Case
Litigation Case Type [Domain]
Liabilities and Stockholders’ Equity
Liabilities And Stockholders Equity [Abstract]
Document Period End Date
Document Period End Date
Net Cash Provided By Used In Financing Activities
Net cash provided by financing activities
Nano Tx Licenses Agreement [Member]
Nano Tx Licenses Agreement [Member]
Nano Tx license agreement Member
Common Class A [Member]
Common Class A [Member]
Disclosure of liquidity and going concern text block
Disclosure Of Liquidity And Going Concern Text Block
Liquidity and Going Concern
Stockholders Equity Note [Abstract]
Percentage issuance of common stock
Percentage Issuance Of Common Stock
Percentage issuance of common stock.
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
Operating leases expiry year
Operating Leases Expiry Year
Operating leases, expiry year.
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total
Stock-based compensation
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
Common Class B [Member]
Common Class B [Member]
Sale of Stock, Consideration Received on Transaction
Consideration to purchaser in cash
Percentage of non-dilutive monetary awards required to pay.
Percentage of Non-dilutive Monetary awards Required to Pay
Percentage of non-dilutive monetary awards required to pay
Series C Convertible Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
Series C convertible preferred stock.
Trading Symbol
Trading Symbol
First payment received
First Payment Received
First Payment Received
Variable Rate
Variable Rate [Axis]
Stockholders' equity
Total stockholders' deficit
Stockholders' deficit
Balance
Balance
Stockholders Equity
Pre-clinical Research Study Obligations [Member]
Pre Clinical Research Study Obligations [Member]
Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.
Class of warrant outstanding
Class Of Warrant Or Right Outstanding
Pre -Funded Warrants to Purchase
Derivative Instrument
Derivative Instrument Risk [Axis]
Sale of Stock, Number of Shares Issued in Transaction
Number of shares issued
Option for exclusive worldwide license
Option For Exclusive Worldwide License
Option for exclusive worldwide license.
Goodwill, Ending Balance
Goodwill, Beginning Balance
Goodwill, Total
Goodwill
Goodwill
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
Issuance of warrants
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]
Change in accounting principle, accounting standards update, adopted
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total
Total unamortized compensation cost related to outstanding unvested stock options and restricted stock awards
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
Additional Subscription.
Additional Subscription [Member]
Outstanding Warrants and Options [Member]
Outstanding Warrants and Options [Member]
Outstanding warrants and options.
Series B Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Series B convertible preferred stock.
Disposal Group Classification
Disposal Group Classification [Axis]
Measurement Input Type [Axis]
Vested and expected to vest at September 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Percentage of aggregate amount of proceeds awarded under CPRIT grant
Percentage Of Aggregate Amount Of Proceeds Awarded Under CPRIT Grant
Percentage of aggregate amount of proceeds awarded under CPRIT grant.
Number of votes per share.
Number Of Votes Per Share
Fair Value Measurements
Fair Value Measurement Inputs Disclosure [Text Block]
Class of Stock [Line Items]
Class Of Stock [Line Items]
Measurement Input, Price Volatility [Member]
Expected Volatility [Member]
Closing bid price for common stock had fallen below
Closing Bid Price For Common Stock Had Fallen Below
Closing bid price for common stock had fallen.
Security Exchange Name
Security Exchange Name
Fair Value by Liability Class [Domain]
Maintain minimum market value of listed securities
Maintain Minimum Market Value of Listed Securities
Maintain minimum market value of listed securities
Total operating expenses
Operating Expenses
Measurement Input, Risk Free Interest Rate [Member]
Risk-free Interest Rate [Member]
Payments for principal, interest and fees
Payments For Loans
Issuance of common stock for in process research and development
Stock Issued During Period, Value, Issued for Services
Class of Stock
Statement Class Of Stock [Axis]
Legal Entity
Legal Entity [Axis]
CPRIT grant funding term, description
CPRIT Grant Funding Term
CPRIT grant funding term.
Research and Development Arrangement, Contract to Perform for Others, Type
Research And Development Arrangement Contract To Perform For Others Type [Domain]
Subsequent Event
Subsequent Event [Member]
Maximum [Member]
Maximum [Member]
Total liabilities and stockholders' deficit
Liabilities And Stockholders Equity
Operating Lease Right Of Use Asset
Operating lease right-of-use assets
Supplemental disclosure of cash flows information:
Supplemental Cash Flow Information [Abstract]
Prime Rate [Member]
Prime Rate [Member]
Earnings Per Share, Diluted, Total
Earnings Per Share Diluted
Net loss per share of common stock - diluted
Net loss per share of common stock - basic
Asset Acquisition [Line Items]
Stock issued during period reverse stock splits, shares
Stock Issued During Period, Shares, Reverse Stock Splits
Total liabilities
Liabilities
Long term debt outstanding threshold amount
Long Term Debt Outstanding Threshold Amount
Long term debt outstanding threshold amount.
Fair Value Hierarchy and NAV [Domain]
Total current assets
Assets Current
Net cash used in investing activities
Net Cash Provided By Used In Investing Activities
Master services agreement terms, Description
Master Services Agreement Terms Description
Master services agreement Terms description.
Measurement Input, Common Stock Market Price.
Measurement Input, Common Stock Market Price [Member]
Common Stock Market Price [Member]
Sale of common stock, net
Issue and sale of share
Sale and issuance of common stock, net (in shares)
Stock option vesting period
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
Lessee, operating lease, existence of option to extend [true false]
Lessee Operating Lease Existence Of Option To Extend
Distribution Type [Axis]
Entity Filer Category
Entity Filer Category
2020 Purchase Agreement [Member]
Twenty Twenty Purchase Agreement [Member]
Twenty twenty purchase agreement.
Asset Acquisition [Domain]
Number of warrants exercised
Number Of Warrants Exercised
Number of warrants exercised
Deferred grant liability
Increase Decrease In Deferred Grant Liability
Increase (decrease) in deferred grant liability.
Net Income (Loss) Available to Common Stockholders, Diluted
Net loss attributable to common stockholders - diluted
Net loss attributable to common stockholders - diluted
Fair value of warrant liability reclassified to equity
Fair Value of Warrant Liability Reclassified to Equity
Fair Value of Warrant Liability Reclassified to Equity
Amount to be received as award for research and development
Amount To Be Received As Award For Research And Development
Amount to be received as award for research and development.
Current Fiscal Year End Date
Current Fiscal Year End Date
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant issuance costs.
Warrant Issuance Costs
Warrant issuance costs
Warrant issuance costs
Private Placement and Prefunded Warrant.
Private Placement and Prefunded Warrant[Member]
Private Placement and Pre-Funded Warrant [Member]
Share-based compensation expense
Share-Based Payment Arrangement, Noncash Expense, Total
Share Based Compensation
Balance as of December 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Related Party
Related Party Transactions By Related Party [Axis]
Fees amount associated with loan
Debt Instrument Fee Amount
Entity Registrant Name
Entity Registrant Name
Number of Reportable Segments
Number of reportable segment
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Loss per Share
Earnings Per Share [Text Block]
Maturity date
Debt Instrument Maturity Date
Entity Emerging Growth Company
Entity Emerging Growth Company
Recorded Unconditional Purchase Obligation [Table]
Recorded Unconditional Purchase Obligation [Table]
Accounting Standards Update 2016-13 [Member]
ASU 2016-13
Money Market [Member]
Money Market Funds [Member]
Purchase of intangible assets
Purchases of intangible assets
Payments to Acquire Intangible Assets
Weighted average shares of common stock outstanding - basic
Weighted average number of shares of common stock outstanding - basic
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted Average Number Of Shares Outstanding Basic
Number of maximum common shares can be resale
Number of Maximum Common Shares Can Be Resale
Number of maximum common shares can be resale.
Distribution Type [Domain]
Litigation Case
Litigation Case [Axis]
Medidata Solutions, Inc. [Member]
Medidata Solutions Inc [Member]
Medidata solutions, inc.
Common stock, shares authorized (in shares)
Common Stock Shares Authorized
Proceeds from sale of common stock, net of offering costs of $0.2 million
Proceeds from sale of common stock, net
Proceeds From Issuance Of Common Stock
Level 1 [Member]
Fair Value, Inputs, Level 1 [Member]
Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total
Accounts payable and accrued expenses
Increase Decrease In Accounts Payable And Accrued Liabilities
Debt Disclosure [Abstract]
Granted (in dollars per share)
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
Financial Instrument
Financial Instrument [Axis]
Balance as of September 30, 2024
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Proceeds from Issuance of Warrants
Proceeds from issuance of warrants
Treasury stock (at cost, 258,425 and 78,559 shares as of September 30, 2024 and December 31, 2023, respectively)
Treasury Stock, Common, Value
Treasury stock (at cost, 258,425 and 78,559 shares as of June 30, 2024 and December 31, 2023, respectively)
purchase price of share.
purchase price of share
Purchase price of share
Long-Term Line of Credit, Total
Long-Term Line of Credit
Line of credit
Reverse stock split effective date
Reverse Stock Split Effective Date
Reverse stock split effective date.
Stockholders' deficit:
Stockholders Equity [Abstract]
Supplemental schedule of non-cash investing and financing activities:
Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]
Litigation settlement, expense
Litigation Settlement Expense
Statement [Table]
Statement [Table]
Segment Reporting, Policy [Policy Text Block]
Segment Information
Vested and expected to vest at September 30, 2024
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
Subsequent Event [Table]
Other current assets
Increase Decrease In Other Current Assets
Weighted Average Exercise Price [Roll Forward]
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward
Preferred stock, shares authorized (in shares)
Preferred Stock Shares Authorized
Fair value loss on warrant liability
Change in fair value of warrants
Change in fair value of warrants
Gain on change in fair value of warrant liabilities
Disposal Group Classification
Disposal Group Classification [Domain]
Entity File Number
Entity File Number
Net decrease in cash and cash equivalents
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
Revenue from Contract with Customer [Abstract]
Earnings Per Share [Abstract]
Per share information:
Warrants expected term
Warrants And Rights Outstanding Term
Warrant liability, Expected term
Biocept Agreement [Member]
Biocept Agreement [Member]
Biocept Agreement.
Statement Of Financial Position [Abstract]
Operating Income Loss
Loss from operations
Accrued license payable.
Accrued License Payable
Accrued payments due to NanoTx
Entity Shell Company
Entity Shell Company
Line of Credit Facility [Table]
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
Summary of Key Inputs Used in Valuation of Liability Classified Warrants
Entity Tax Identification Number
Entity Tax Identification Number
Assets
Assets [Abstract]
Class of Warrant or Right
Class Of Warrant Or Right [Domain]
Entity Current Reporting Status
Entity Current Reporting Status
Exercisable at September 30, 2024
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
Asset Acquisition [Text Block]
Biocept Asset Acquisitions
Subsequent Events [Abstract]
Grant Revenue Recognition
Revenue from Contract with Customer [Policy Text Block]
Biocept asset acquisitions.
Biocept Asset Acquisitions [Member]
Biocept Asset Acquisitions [Member]
Document Fiscal Year Focus
Document Fiscal Year Focus
Aggregate gross proceeds from sales of common stock
Gross Proceeds from Issuance of Common Stock
Gross proceeds from issuance of common stock.
Change in Accounting Principle, Accounting Standards Update, Adoption Date
Change in accounting principle, accounting standards update, adoption date
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively
Preferred Stock Value
Repayments of Long-Term Debt, Total
Repayments Of Long Term Debt
Principal payments of term loan obligation
Series U Warrants [Member]
Series U Warrants [Member]
Series U warrants member
Purchase of treasury stock
Purchase of treasury stock
Treasury Stock, Value, Acquired, Cost Method
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
Department of Defense Award [Member]
Department of Defense Award [Member]
Department of defense award.
Proceeds from sale of common stock, net of offering costs of $0.2 million
Proceeds From Issuance Of Common Stock Net of Offering Costs
Proceeds from issuance of common stock net of offering costs.
City Area Code
City Area Code
Warrants and Rights Outstanding, Measurement Input
Warrant liability, Measurement input
Total current liabilities
Liabilities Current
Change in fair value of liability instruments
Liabilities Fair Value Adjustment
Derivative Contract
Derivative Contract Type [Domain]
Stock issued for research and development
Stock Issued for Research and Development
Stock issued for research and development.
Maximum grant amount to be received as per grant contract
Maximum Grant Amount to be Received as per Grant Contract
Maximum grant amount to be received as per grant contract.
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Local Phone Number
Local Phone Number
Preferred Stock, Shares Outstanding, Ending Balance
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred stock, shares outstanding (in shares)
Preferred Stock Shares Outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Sales order term
Sales Order Term
Sales order term.
Additional Paid in Capital, Total
Additional paid-in capital
Additional Paid In Capital
Fractional adjustment of common stock.
Fractional Adjustment of Common Stock
Fractional adjustment
Commitments And Contingencies Disclosure [Abstract]
Shares issued
Remaining common stock issued and sold (in shares)
Shares Issued
Treasury stock
Treasury Stock, Value
Treasury Stock, Value, Total
Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Master service agreement date
Master Services Agreement Date
Master services agreement date.
Master services agreement initial term
Master Services Agreement Initial Term
Master services agreement initial term.
Less: current portion
Operating lease liability
Operating Lease Liability Current
Right-of-use assets obtained in exchange for operating lease liability
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability
Grant funding period
Grant Funding Period
Grant funding period.
Series B Warrant.
Series B Warrant [Member]
Interest rate
Debt Instrument, Interest Rate, Stated Percentage
Accumulated Deficit [Member]
Retained Earnings [Member]
Amortization of Debt Issuance Costs and Discounts, Total
Amortization of deferred financing costs and debt discount
Amortization Of Financing Costs And Discounts
Basic and diluted net loss per share of common stock calculation:
Earnings Per Share, Basic [Abstract]
Payments to Acquire Property, Plant, and Equipment, Total
Purchases of property and equipment
Payments To Acquire Property Plant And Equipment
In process research and development acquired
Cash Paid For I P R D Asset Acquired In An Asset Acquisition
Cash paid for IPRD asset acquired in an asset acquisition.
Amendment and restatements May 2024 private placement.
Amendment and Restatements May 2024 Private Placement [Member]
Document Transition Report
Document Transition Report
Authorized amount of repurchase of stock
Share Repurchase Program, Authorized, Amount
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Subscription Agreement [Member]
Subscription Agreement [Member]
Subscription and Investment Representation Agreement
Use of Estimates
Use Of Estimates [Text Block]
Provides an entity's explanation that the preparation of financial statements in conformity with generally accepted accounting principles requires the use of management estimates.
Unpaid offering cost
Unpaid Offering Costs
Unpaid Offering Costs.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Minimum [Member]
Minimum [Member]
Common Stock [Member]
Common Stock [Member]
Vested and expected to vest at September 30, 2024
Vested and expected to vest at September 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Operating Lease, Right-of-Use Asset, Periodic Reduction
Amortization of operating lease right-of-use assets
Additional Paid-in Capital [Member]
Additional Paid In Capital [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]
Securities purchase agreement.
Securities Purchase Agreement [Member]
Other assets
Other Assets Noncurrent
Series A Warrant.
Series A Warrant [Member]
Remained authorized amount for repurchase
Share Repurchase Program, Remaining Authorized, Amount
Other current assets
Other Assets Current
Entity Common Stock, Shares Outstanding
Entity Common Stock Shares Outstanding
Disaggregation of Revenue [Line Items]
Debt instrument, covenant compliance
Debt Instrument Covenant Compliance
Basis of Presentation and New Accounting Standards
Basis Of Accounting Policy Policy [Text Block]
Non-cash financing expense.
Non-Cash Financing Expense
Non-cash financing expense
Available-for-Sale Securities
Debt Securities, Available-for-Sale, Premium on Purchased Options [Policy Text Block]
Common stock, $0.001 par value; 100,000,000 shares authorized; 6,154,758 and 5,896,333 issued and outstanding at September 30, 2024, and 4,522,656 issued and 4,444,097 outstanding as of December 31, 2023, respectively
Common stock, $0.001 par value; 100,000,000 shares authorized; 36,123,833 and 33,601,373 issued and outstanding at March 31, 2023 and December 31, 2022, respectively
Common Stock Value
Voting stock, value
Asset Acquisition [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Line of Credit, Current
Line of credit
License fee payment in cash
Payments For Royalties
Interest income
Investment Income Interest
Number of preferred stock, shares converted
Number Of Preferred Stock Shares Exercised
Number Of Preferred Stock Shares Exercised.
Summary of Financial Assets Measured at Fair Value on Recurring Basis
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
Intangible assets, net
Other Intangible Assets Net
Origination date
Debt Instrument Offering Date1
Percentage of credit facility cannot exceed collateralized marketable securities.
Percentage of Credit Facility Cannot Exceed Collateralized Marketable Securities
Percentage of credit facility cannot exceed collateralized marketable securities
Present value of obligations under leases
Operating Lease Liability
Lease liability
Measurement Frequency [Axis]
Commitments And Contingencies
Commitments and contingencies (Note 10)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Restricted beneficial ownership level result of exercise of warrant to receive pre-funded warrant.
Restricted Beneficial Ownership Level Result of Exercise of Warrant To Receive Pre-funded Warrant
Restricted beneficial ownership level result of exercise of warrant to receive pre-funded warrant
Weighted average shares of common stock - diluted
Weighted average number of shares of common stock outstanding - diluted
Weighted Average Number of Shares Outstanding, Diluted, Total
Weighted Average Number Of Diluted Shares Outstanding
Research and Development Arrangement, Contract to Perform for Others, Type
Research And Development Arrangement Contract To Perform For Others By Type [Axis]
Lessee, operating lease, renewal term
Lessee Operating Lease Renewal Term
Vested and expected to vest at September 30, 2024 (in shares)
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
Entity Small Business
Entity Small Business
Common stock, reverse stock split, fractional shares issued
Stock Issued During Period, Shares, Stock Splits
Basis variable rate
Debt Instrument Basis Spread On Variable Rate1
Term Loan Obligations
Debt Disclosure [Text Block]
Pre-funded warrants member.
Pre-Funded Warrants [Member]
Pre-Funded Warrants [Member]
Issuance of common stock for in process research and development (in shares)
Stock Issued During Period, Shares, Issued for Services
Revenue recognized
Revenue
Revenues
Revenues, Total
Stockholders' Equity Note, Stock Split, Conversion Ratio
Stock split conversion ratio
Treasury Bills and Government Agency Bonds [Member]
US Treasury Securities [Member]
Purchase of treasury stock (in Shares)
Purchase of treasury stock (in Shares)
Treasury Stock, Shares, Acquired
Accounting Standards Update and Change in Accounting Principle [Table]
Line of Credit Facility [Abstract]
Credit Facility [Axis]
Contractual Obligation, Total
Contractual obligation
Contractual Obligation
Accretion of discount on short-term investments
Accretion (Amortization) of Discounts and Premiums, Investments
Series a warrant and series b warrant.
Series A Warrant and Series B Warrant [Member]
Net Cash Provided By Used In Financing Activities [Abstract]
Cash flows provided by financing activities:
Balance as of September 30, 2024 (in dollars per share)
Balance as of December 31, 2023 (in dollars per share)
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
Non-cash amortization
Amortization Of Debt Discount Premium
Interest rate
Debt Instrument Floating Interest Rate Percentage
Floating interest rate for funds borrowed, under the debt agreement.
CPRIT Contract [Member]
Cancer Prevention And Research Institute Of Texas Contract [Member]
Cancer prevention and research institute of texas contract.
Line of Credit Facility, Commitment Fee Percentage
Applicable fees
Measurement Frequency [Domain]
2020 Plan [Member]
Stock Based Compensation2020 Equity Incentive Plan [Member]
Stock based compensation 2020 equity incentive plan.
Net income from continuing operations
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent, Total
Level 3 [Member]
Fair Value, Inputs, Level 3 [Member]
Operating lease, weighted average remaining term
Operating Lease Weighted Average Remaining Lease Term1
Subsequent Events
Subsequent Events [Text Block]
Warrant Liability
Warrant Liability
Warrant liability
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]
Change in accounting principle, accounting standards update, immaterial effect
Risks And Uncertainties [Abstract]
Debt instrument floor rate.
Debt Instrument Floor Rate
Debt instrument floor rate
Accounts Payable and Accrued Liabilities, Current, Total
Accounts payable and accrued expenses
Accounts Payable And Accrued Liabilities Current